SPOTLIGHT -
September 24th 2024
A new analysis from a 3-year open-label extension study revealed that treatment with deutetrabenazine was associated with long term improvement of symptoms of tardive dyskinesia.
June 3rd 2024
Rakesh Jain, MD, shares more about the recent approval of Austedo XR for the treatment of tardive dyskinesia and Huntington disease chorea control.
May 30th 2024
The FDA has approved Austedo XR as a once-daily pill treatment option for tardive dyskinesia and Huntington disease chorea control.
May 22nd 2024
Check out new data from phase 3 study of Ingrezza for the real-world management of tardive dyskinesia.
May 7th 2024
Here are highlights from the third day of this year’s APA Annual Meeting.
Early Stages of Tardive Dyskinesia
A reader asks an expert about differential features distinguishing between early stages of tardive dyskinesia and motor tics.
Read More